Business Wire

TX-CIRRUS-LOGIC

25.6.2024 15:01:32 CEST | Business Wire | Press release

Share
Cirrus Logic Unveils Its Latest Additions to Its Family of Professional Audio Converters

Cirrus Logic (Nasdaq: CRUS) today unveiled the latest devices in its Pro Audio product family: a series of digital-to-analog converters (DACs) and an ultra-high performance audio CODEC that set a new standard for the prosumer and professional audio markets. These new solutions cater to the needs of recording artists, live performers, and audiophiles, delivering transparent audio converters to ensure recording and playback without any compromise in sound quality.

This launch expands on last year's successful analog-to-digital converters (ADCs) launch. Crafted with a focus on superior analog functionality and digital integration, these devices from Cirrus Logic offer exceptional performance, minimal power requirements, and innovative features like hybrid gain control, addressing longstanding audio challenges in the industry.

“True transparency in audio—that’s the hallmark of Cirrus Logic’s Pro Audio Family. It’s not just about sound, it’s about the authenticity from creation to consumption. Our commitment is purity in audio reproduction, ensuring that what you hear is as true to the original as possible,” said Eddie Sinnott, Director of Product Marketing. “With this new series of flagship audio products, we’re setting a gold standard for both professionals and prosumers, enabling our customers to create distinctive products with the confidence of our world-class engineering and support.”

Cirrus Logic CS4308P/CS4304P/CS4302P DACs and CS4282P CODEC

Designed with ease of use in mind, the Cirrus Logic Pro Audio 8-channel DAC CS4308P, 4-channel CS4304P, 2-channel CS4302P and CODEC CS4282P seamlessly integrate within a wide range of audio equipment. These new devices offer configurable advanced digital filters allowing our customers to define their signature sound. Cirrus Logic designs the devices with users in mind, making them as simple as possible to integrate and extract their full potential.

“As a long-time user of Cirrus Logic, we are excited about the new additions to its family of DAC and CODEC products being launched today,” said Simon Jones, CTO, Focusrite Group. “Cirrus Logic’s desire to keep setting the benchmark in audio quality is evident. These devices are designed to flawlessly integrate with a diverse spectrum of audio equipment, from USB audio interfaces to professional speakers and musical instruments. The addition of a hybrid gain control system into the CODEC and new ADC’s is a game changer for system integration that we really appreciate. At Focusrite, crafting audio interfaces is not just our business; it’s our passion. We bridge the gap between the artist and the audience, ensuring the sound conveyed is pristine.”

Exceptional Efficiency with Leading-Edge performance

The Pro Audio family also offers industry-leading power efficiency at 10 mW/ch for the 8/4-channel DACs, underlining Cirrus Logic’s longstanding commitment to bringing energy-efficient products to market. These new devices are 32-bit offering sample rates of up to 768 kHz, providing 129 dB of dynamic range for the CS4302P/CS4282P and 123 dB for the CS4304/8P. THD+N for these devices are all -114 dB or lower.

Product Availability

Samples of the CS4304/8P DACs and the CS4282P are available to order now. The converters are controllable and configurable using Cirrus Logic’s SoundClear® Studio software, which is available at www.cirrus.com. Samples of the CS4302P DAC will follow, later in the year.

Cirrus Logic Inc.

Cirrus Logic is a leader in low-power, high-precision mixed-signal processing solutions that create innovative user experiences for the world’s top mobile and consumer applications. With headquarters in Austin, Texas, Cirrus Logic is recognized globally for its award-winning corporate culture. Check us out at www.cirrus.com.

Cirrus Logic, Cirrus and the Cirrus Logic logo are registered trademarks of Cirrus Logic, Inc. All other company or product names noted herein may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625199957/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye